Seres Therapeutics announced that its Phase 1b trial results for SER-155, a live biotherapeutic designed to reduce bloodstream infections (BSIs) in allogeneic hematopoietic cell transplant (allo-HCT) patients, were published in Nature Medicine. The study showed a 77% relative risk reduction in BSIs compared to placebo, along with significantly lower antibiotic use and improved gut barrier integrity. SER-155 was well tolerated and has received FDA Breakthrough Therapy and Fast Track designations, with plans for a Phase 2 trial pending funding. The therapy also shows promise for treating immune-related gut inflammation in cancer patients, potentially allowing continued cancer treatment without immunosuppressive drugs.
Seres Therapeutics' recent Phase 1b trial results highlight a 77% relative risk reduction in bloodstream infections for allo-HCT patients. For readers following health-sector stocks, here is Pluang's market snapshot as of Nov 03, 2026 19:02 WIB: out of 150 priced US health stocks, 74 rose and 69 fell. Notable movers include INO at USD 1.78 with a 5.56% decline, NUWE at USD 4.90 down 5.41%, and AHCO at USD 6.20 up 4.91%, with typical hold times ranging from 21 to 42 days and varied buy/sell order activity.
Anavex Life Sciences appointed Terrie Kellmeyer, Ph.D., as President and CEO, also joining the Board. Kellmeyer, with over 30 years in biopharma, has led the company through key clinical milestones including FDA clearance for Fragile X syndrome trial...
Cardiff Oncology, a clinical-stage biotech company focusing on cancer therapies via PLK1 inhibition, announced it will present at the UBS Global Biopharma Conference on November 16-17, 2026. The company's CEO, Mani Mohindru, will deliver a fireside c...
Seyond Inc is enhancing its smart city solutions by integrating advanced LiDAR 3D sensing with AI-powered analytics and collaborations with Dell Technologies, NVIDIA, and AMSYS. This expansion supports improved safety, transportation, and infrastruct...
Stella-Jones Inc. announced a teleconference on November 4, 2026, at 10:00 AM EST to discuss its third-quarter 2026 financial results. The event is open to investors, analysts, and interested parties, with live streaming and phone access provided. A ...
Stella-Jones Inc. announced a conference call for November 4, 2026, at 10:00 AM EST to discuss its third quarter 2026 financial results. The call is open to investors, analysts, and interested parties and will be webcast live with a recording availab...
